Welcome to our dedicated page for Bone Biologics SEC filings (Ticker: BBLGW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Bone Biologics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Bone Biologics's regulatory disclosures and financial reporting.
Bone Biologics (Nasdaq: BBLG / BBLGW) filed an 8-K (Item 8.01) reporting that Nasdaq’s Listing Qualifications Department confirmed on June 25 2025 the company has regained compliance with Listing Rule 5550(a)(2), which requires a minimum bid price of $1 per share. The confirmation removes the prior deficiency notice and the immediate risk of delisting from the Nasdaq Capital Market.
The disclosure, delivered via a press release furnished as Exhibit 99.1, contains no additional financial data, share issuances, or operational updates. By maintaining its listing, the company preserves liquidity, institutional access, and market visibility—factors critical to future capital-raising efforts.